EPAM Systems (EPAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 May, 2026Voting matters and shareholder proposals
Proposal 5 seeks to amend the 2025 Long Term Incentive Plan by adding 4,000,000 additional shares for equity compensation programs, with the Board unanimously recommending approval.
Glass Lewis supports Proposal 5, while ISS recommends against it, citing concerns detailed in their analysis.
Approval of Proposal 5 is positioned as essential for attracting, retaining, and motivating employees and executives, especially in a competitive technology talent market.
The additional shares are expected to provide flexibility for approximately two years, after which further amendments would require shareholder approval.
Saratoga Proxy Consulting LLC has been engaged to assist in proxy solicitation for a fee of approximately $20,000 plus expenses.
Executive compensation and say-on-pay
Equity compensation, split between performance and time-vesting restricted stock units, comprised about 70% of named executive officer compensation in 2025.
86% of equity awards in 2025 were granted to employees other than named executive officers.
ISS recommended a vote FOR the 2025 named executive officer compensation say-on-pay proposal, reflecting a disciplined approach.
Board of directors and corporate governance
In September 2025, a CEO succession plan was executed, with the co-founder transitioning to Executive Chair and a new President and CEO appointed.
The 2025 Plan includes stockholder-friendly governance features such as no liberal share recycling, no repricing of stock options without approval, and robust clawback provisions.
Regular engagement with stockholders informs compensation and governance practices, with over 25% of outstanding shares represented in 2025 discussions.
Latest events from EPAM Systems
- Q1 2026 revenue up 7.6% to $1.4B, with strong EPS and major share repurchases.EPAM
Q1 20267 May 2026 - Accelerating AI-native transformation and targeting double-digit growth with robust margins.EPAM
Investor Day 20264 May 2026 - Shareholders will vote on seven key proposals, including governance and compensation changes.EPAM
Proxy filing15 Apr 2026 - Annual meeting covers director elections, auditor ratification, and key shareholder rights proposals.EPAM
Proxy filing6 Apr 2026 - Board backs governance, compensation, and equity plan changes; opposes lower special meeting threshold.EPAM
Proxy filing6 Apr 2026 - Shareholders will vote on director elections, equity plan amendments, and expanded governance rights.EPAM
Proxy filing26 Mar 2026 - Strong 2025 growth and AI momentum support a robust 2026 outlook for revenue and EPS.EPAM
Q4 202519 Feb 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q3 revenue and EPS rose, NEORIS acquisition expanded reach, and share buybacks accelerated.EPAM
Q3 202416 Jan 2026